Schedule template 1													
Date of publication: 30/06/2018													
	Full Name (Art. 1.01)	HCOs: city where registered (Art. 3)	Country of Principal Practice (Schedule 1)	Principal Practice Address (Art. 3)	Unique country local identifyer <i>OPTIONAL</i> (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)				Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)			
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accomodation	Fees	Related expenses agreed in the fee for service or consultancy contract	TOTAL OPTIONAL	
	INDIVIDU	AL NAMED DIS	CLOSURE - or	te line per HCP (i.e. all transfers of value during a year for an i	individual HCP v	vill be summed N/A	up: itemization should be av	vailable for the individual R	ecipient or public authorities	s' consultation o	only, as appropriate)		
ď	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed o							•					
호	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2					N/A	N/A	-	2 518,00	651,10	-	3 169,10	
	Number of Recipients in aggregate disclosure- Art. 3.2					N/A	N/A	-	3	3	-		
	% of the number Recipients included in the aggregate disciosure in the total number of Recipients disclosed Art. 3.2					N/A	N/A		100%	100	-		
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or pul									authorities' consultation only, as appropriate)			
	Klinicki Centar Srbije	Beograd	Serbia			-	-	-	-	688,60	-	688,60	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
os	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2					-	-	-	-	-	-		
유	Number of Recipients in aggregate disclosure- Art. 3.2					-	-	-	-	-	-		
	% of the number Recipients included in the aggregate disciosure in the total number of Recipients disciosed Art. 3.2					-	-	-	-	-	-		
	AGGREGATE DISCLOSURE												
R&D	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											10 721,70	